Chapter 4 · Associated Medical Professionals of New York · New York
Benign Prostatic Hyperplasia and Male LUTS
BPH-related lower urinary tract symptoms are bread-and-butter urology and a large share of your clinic. The AUA released an updated BPH/LUTS guideline in 2026 that reorganized the evidence and adjusted several recommendations (procedural options…
Saved privately in this browser and shared across state tabs.
BPH-related lower urinary tract symptoms are bread-and-butter urology and a large share of your clinic. The AUA released an updated BPH/LUTS guideline in 2026 that reorganized the evidence and adjusted several recommendations (procedural options expanded; prostatic artery embolization upgraded). This chapter gives you a practical framework for diagnosis, medical management, and — critically at Advanced Urology — knowing when to stop prescribing and fix the problem.
4.1 What is actually happening
BPH is histologic hyperplasia of the transition zone of the prostate — an androgen-dependent, age-related process. It causes symptoms through two mechanisms, and separating them explains why treatments work the way they do:
Static component: the physical bulk of adenoma obstructing the urethra. This is what 5-alpha-reductase inhibitors shrink, and what UroLift, PAE, and resective/enucleative procedures address.
Dynamic component: smooth-muscle tone in the prostate and bladder neck, mediated by alpha-1a adrenergic receptors. This is what alpha-blockers relax — which is why they work within days.
Over time, chronic obstruction causes secondary bladder changes: detrusor hypertrophy and instability (producing the storage symptoms that often bother patients most), then, if untreated, detrusor decompensation and an underactive bladder — a state that no prostate procedure fully reverses. This is a key reason we do not leave men on pills for a decade.
4.2 Evaluation
History — characterize storage vs. voiding symptoms (Chapter 1), quantify with the IPSS (International Prostate Symptom Score, 0–35) plus the separate bother/quality-of-life question, and screen for red flags. Ask specifically about the medication list (anticholinergics, antihistamines, decongestants, opioids, diuretic timing), fluid and caffeine/alcohol habits, and constipation.
Exam and objective data — prostate ultrasound to measure gland volume (which drives the procedural choice — UroLift vs. PAE — in Section 4.6); a focused neurologic exam if indicated; urinalysis (mandatory — exclude infection and hematuria); PSA when appropriate with shared decision-making (Chapter 8); post-void residual by bladder scan; and uroflowmetry when available (Qmax < 10 mL/s with an adequate voided volume suggests obstruction; 10–15 is equivocal). Consider a voiding diary when nocturia or polyuria dominates. Renal function if retention or high PVR. Do not use DRE to estimate prostate size; ultrasound provides a far more accurate gland-volume measurement. MRI can also provide volume when already available.
IPSS band |
Score |
General approach |
Mild |
0–7 |
Watchful waiting + lifestyle; treat only if bothered |
Moderate |
8–19 |
Medical therapy or a procedure, based on bother and patient preference |
Severe |
20–35 |
Treat; low threshold for a definitive procedure |
The bother score matters more than the raw IPSS. A man with an IPSS of 20 who is not bothered may need nothing; a man with an IPSS of 9 who is up four times a night and miserable needs treatment.
BPH red flags — do not just start a pill
|
4.3 The differential — do not call everything BPH
Mimic |
How to spot it |
Urethral stricture |
Younger patient; prior instrumentation, catheter, STI, or straddle trauma; flat “plateau” curve on uroflow; difficulty passing a catheter (Chapter 14) |
Underactive/hypocontractile bladder |
Long-standing obstruction, diabetes, or neurologic disease; high PVR with weak stream but a low-pressure, low-flow pattern on urodynamics (Chapter 25) |
Neurogenic bladder |
Known MS, Parkinson's, stroke, spinal pathology, or diabetes; associated bowel/sexual dysfunction (Chapter 25) |
Bladder cancer / CIS |
Irritative symptoms plus hematuria; a normal-sized prostate. Do the cystoscopy |
Primary OAB |
Storage symptoms dominate; PVR is normal; the flow is fine (Chapter 5) |
Nocturnal polyuria |
Large nighttime volumes on the diary; CHF, sleep apnea, edema, or evening fluids — not a prostate problem (Chapter 5) |
Chronic prostatitis / CPPS |
Pain is the dominant complaint, not obstruction (Chapters 6 and 27) |
4.4 Lifestyle and behavioral measures
Limit evening fluids (nothing 2–3 hours before bed), and cut caffeine and alcohol — both are bladder irritants and diuretics.
Time diuretics earlier in the day (a mid-afternoon dose is often the single most effective fix for nocturia).
Treat constipation aggressively — a loaded rectum genuinely worsens voiding.
Review and stop the medications that worsen symptoms: antihistamines, decongestants (pseudoephedrine), anticholinergics, and opioids.
Bladder training, timed voiding, and double-voiding (void, wait 30 seconds, void again).
Weight loss and exercise — metabolic syndrome is independently associated with BPH progression.
4.5 Medical therapy
Medication controls symptoms but does not cure the obstruction, and Advanced Urology's philosophy is to use it as a bridge to a definitive, minimally invasive solution rather than a lifelong crutch — particularly given the cognitive concerns discussed below.
Class |
Examples & dosing |
Role & counseling points |
Alpha-blockers |
Tamsulosin 0.4 mg daily; alfuzosin 10 mg; silodosin 8 mg; doxazosin/terazosin titrated from 1 mg qHS |
Fast symptom relief (days), improving IPSS ~4–6 points. Reasonable as a short-term bridge. our practice position: avoid open-ended use beyond ~1 year — favor a definitive procedure. Watch orthostatic hypotension (worst with doxazosin/terazosin) and intraoperative floppy iris syndrome — tell the eye surgeon before cataract surgery. Retrograde ejaculation is common with tamsulosin and especially silodosin. Long-term cognitive caution: observational studies have reported an association between alpha-blocker exposure — especially tamsulosin — and incident dementia, but the evidence is conflicting and does not establish causation. If treatment is expected to extend beyond ~2 years, reassess cognition, ongoing need, orthostasis/falls, and definitive BPH options with the patient and family. |
5-alpha-reductase inhibitors (5-ARI) |
Finasteride 5 mg daily; dutasteride 0.5 mg daily |
Shrink larger glands (best in prostates ≥ ~30–40 mL) by ~20–25% over 6–12 months; the only class shown to reduce the risk of retention and the need for surgery. Slow onset (months). Lowers PSA by ~50% — double the value to interpret. Sexual side effects (libido, ED, ejaculatory) and gynecomastia; counsel per current safety data. Also our drug for prostatic bleeding (Chapter 2). |
Combination (alpha-blocker + 5-ARI) |
e.g., tamsulosin + dutasteride |
Superior to either alone for larger glands and higher progression risk (the MTOPS/CombAT lesson). Again best viewed as a bridge to definitive therapy at our practice. |
PDE5 inhibitor |
Tadalafil 5 mg daily |
Improves LUTS and treats concurrent ED — an elegant single answer for the man with both. Do not combine with nitrates; caution with alpha-blockers (additive hypotension). |
Beta-3 agonist |
Mirabegron 25–50 mg; vibegron 75 mg |
Add for predominant storage/OAB symptoms once obstruction and retention risk are assessed — check the PVR first (Chapter 5). |
Anticholinergics |
Oxybutynin, solifenacin, etc. |
our practice strongly advises against these and uses them only very infrequently (dementia, constipation, dry mouth, retention, falls — Chapter 5). If storage symptoms coexist, prefer a beta-3 agonist and treat the obstruction. |
Associated Medical Professionals of New York position — do not leave men on BPH pills indefinitely
Evidence note: A Medicare cohort reported a modest association between tamsulosin and dementia after a median 19.8 months, while other multi-year cohorts did not find increased risk by alpha-blocker type or duration. See PMID 29316005, PMID 30840545, and PMID 35751619. |
4.6 The Associated Medical Professionals of New York procedural approach — sized by the gland
Refer for a procedure when symptoms are refractory to (or the patient wants to get off) medication, when the patient prefers a durable solution, or when complications develop (retention, bladder stones, recurrent infection or bleeding, renal compromise). At Associated Medical Professionals of New York the choice is driven primarily by prostate size, with ejaculatory preservation a priority. Our two workhorse minimally invasive options are UroLift for smaller glands and prostatic artery embolization (PAE) for larger glands.
Gland size |
Preferred our practice option |
Why |
< 50 g |
Prostatic urethral lift (UroLift) |
Minimally invasive implants that hold the lateral lobes open without cutting, heating, or removing tissue. Preserves ejaculation and erectile function; fast recovery; usually no catheter. Best suited to glands under ~50 g without a large obstructing median lobe. |
> 50 g |
Prostatic artery embolization (PAE) |
our practice's preferred definitive therapy for large glands — the new gold standard for the big prostate. It typically reduces prostate size by approximately 40–50% by embolizing its blood supply through a tiny catheter; no urethral resection, typically no catheter or a short one, excellent preservation of sexual function, and it treats glands that are too large for many endoscopic options. |
Figure 4.1 — UroLift. Permanent implants retract the obstructing lateral lobes and hold the prostatic urethra open. No tissue is cut, heated, or removed, which is why ejaculation is preserved.
What PAE actually involves — so you can counsel the patient
No urethral catheter afterward — provided the patient was not already in retention going in. This is one of the strongest selling points for the man who is terrified of a catheter, and it distinguishes PAE from a TURP. Say it explicitly; patients assume the opposite.
What you must order before scheduling: a CT angiogram (the IR team uses it to map the prostatic arterial anatomy, which is variable and occasionally prohibitive) and pre-PAE labs. Get these moving at the visit where you decide on PAE — a missing CTA is the most common reason a case gets delayed.
Insurance can be difficult about PAE. Coverage is inconsistent and payers can be picky. Start the authorization early, set the patient's expectations honestly, and do not promise a date until coverage is confirmed.
Figure 4.2 — Prostatic artery embolization. A microcatheter is navigated from the wrist or groin to each prostatic artery in turn, and microspheres are delivered into BOTH main prostatic arteries. The devascularized adenoma involutes over the following weeks, typically reducing prostate size by approximately 40–50%.
Procedures we do NOT offer, by design: Associated Medical Professionals of New York does not perform Rezūm (water-vapor therapy) or GreenLight/photoselective vaporization (PVP). In our experience the durability and outcomes do not match UroLift and PAE, so we do not use them. Thulium laser enucleation (ThuLEP), TURP, Aquablation, and single-port robotic simple prostatectomy (for very large glands) remain available for specific anatomies and are chosen case by case, but the great majority of patients are best served by UroLift or PAE.
Other procedures (case by case) |
Where they fit |
ThuLEP (thulium laser enucleation) |
Size-independent enucleation with excellent durability; an option for very large glands or when tissue is needed for pathology |
TURP |
The historical benchmark; still appropriate for selected moderate glands |
Aquablation |
Heat-free waterjet resection with an expanded role in the 2026 guideline; option across a range of gland sizes |
Single-port robotic simple prostatectomy |
Very large glands (often > 100–150 g) when an endoscopic approach is not ideal |
Counseling that patients remember
|
BPH-related LUTS are bread-and-butter urology and a large share of your clinic. The AUA released an updated BPH/LUTS guideline in 2026 that expanded procedural options and upgraded prostatic artery embolization. These tracks cover diagnosis, medical management, and — critically at Associated Medical Professionals of New York — knowing when to stop prescribing and fix the problem.
Characterize the symptoms, get the objective data, screen the red flags, and make sure it is actually BPH.
Select a box to open its teaching details.
What is actually happening
BPH is histologic hyperplasia of the transition zone — an androgen-dependent, age-related process. It causes symptoms through two separable mechanisms.
The two components
- Static component — the physical bulk of adenoma obstructing the urethra. This is what 5-ARIs shrink, and what UroLift, PAE, and resective/enucleative procedures address.
- Dynamic component — smooth-muscle tone in the prostate and bladder neck, mediated by alpha-1a adrenergic receptors. This is what alpha-blockers relax — which is why they work within days.
Why we do not wait
Chronic obstruction causes detrusor hypertrophy and instability (the storage symptoms that often bother patients most), then detrusor decompensation and an underactive bladder — a state that no prostate procedure fully reverses. This is a key reason we do not leave men on pills for a decade.
What to capture
- Storage vs. voiding vs. post-micturition breakdown (Ch 1)
- IPSS — International Prostate Symptom Score, 0-35
- The separate bother / QoL question — capture it every time
The number that matters most
The bother score matters more than the raw IPSS. A man with an IPSS of 20 who is not bothered may need nothing; a man with an IPSS of 9 who is up four times a night and miserable needs treatment.
Ask specifically about
- Anticholinergics
- Antihistamines
- Decongestants
- Opioids
- Diuretic timing
- Fluid and caffeine / alcohol habits
- Constipation
Also consider
A voiding diary when nocturia or polyuria dominates.
Exam and tests
- Prostate ultrasound to measure gland volume — which drives the procedural choice, UroLift vs. PAE (Section 4.6)
- A focused neurologic exam if indicated
- Urinalysis — mandatory: exclude infection and hematuria
- PSA when appropriate, with shared decision-making (Ch 8)
- Post-void residual by bladder scan
- Uroflowmetry when available
- Renal function if retention or high PVR
Reading the uroflow
- Qmax < 10 mL/s with an adequate voided volume suggests obstruction
- 10-15 mL/s is equivocal
Our position on prostate sizing
Do not use DRE to estimate prostate size. Use ultrasound for a much more accurate volume measurement.
Better sizing
- Prostate ultrasound provides an accurate gland-volume measurement; MRI can also provide volume when already available
Why it matters here
At our practice the procedural choice is driven primarily by prostate size — the 50 g line between UroLift and PAE. Get the number right before you commit a patient to a plan.
IPSS band — the general approach
Approach
- Watchful waiting + lifestyle
- Treat only if bothered
Approach
- Medical therapy or a procedure, based on bother and patient preference
Approach
- Treat
- Low threshold for a definitive procedure
Red flags
- Refractory or recurrent urinary retention, or a persistently high PVR
- Recurrent UTIs, bladder stones, or gross hematuria attributable to the prostate
- Renal insufficiency from obstruction / bilateral hydronephrosis
- An elevated or rising PSA — evaluate for prostate cancer BEFORE attributing symptoms to BPH (Ch 8)
- Predominant symptoms that do not fit — pure urgency in a young man, or a very poor flow in a 35-year-old: think stricture, not BPH
The differential and how to spot it
- Urethral stricture — younger patient; prior instrumentation, catheter, STI or straddle trauma; flat "plateau" curve on uroflow; difficulty passing a catheter (Ch 14)
- Underactive / hypocontractile bladder — long-standing obstruction, diabetes or neurologic disease; high PVR with a weak stream but a low-pressure, low-flow pattern on urodynamics (Ch 25)
- Neurogenic bladder — known MS, Parkinson's, stroke, spinal pathology or diabetes; associated bowel/sexual dysfunction (Ch 25)
- Bladder cancer / CIS — irritative symptoms plus hematuria; a normal-sized prostate. Do the cystoscopy
- Primary OAB — storage symptoms dominate; PVR is normal; the flow is fine (Ch 5)
- Nocturnal polyuria — large nighttime volumes on the diary; CHF, sleep apnea, edema, or evening fluids — not a prostate problem (Ch 5)
- Chronic prostatitis / CPPS — pain is the dominant complaint, not obstruction (Ch 6 and 27)
Pitfalls
- The two most expensive misses are the stricture treated as BPH and the CIS treated as OAB. Both are caught by asking about instrumentation and looking at the uroflow curve shape, then scoping.
Medication controls symptoms but does not cure the obstruction. At our practice it is a bridge to a definitive minimally invasive solution, not a lifelong crutch.
Select a box to open its teaching details.
our practice framing
Medication controls symptoms but does not cure the obstruction. Associated Medical Professionals of New York's philosophy is to use it as a bridge to a definitive, minimally invasive solution rather than a lifelong crutch — particularly given the cognitive concerns.
What to prescribe as behavior
- Limit evening fluids — nothing 2-3 hours before bed
- Cut caffeine and alcohol — both are bladder irritants and diuretics
- Time diuretics earlier in the day — a mid-afternoon dose is often the single most effective fix for nocturia
- Treat constipation aggressively — a loaded rectum genuinely worsens voiding
- Review and stop the medications that worsen symptoms: antihistamines, decongestants (pseudoephedrine), anticholinergics, opioids
- Bladder training, timed voiding, and double-voiding — void, wait 30 seconds, void again
- Weight loss and exercise — metabolic syndrome is independently associated with BPH progression
Which class do you reach for?
Dosing
- Tamsulosin 0.4 mg daily
- Alfuzosin 10 mg
- Silodosin 8 mg
- Doxazosin / terazosin — titrated from 1 mg qHS
What to expect
Fast symptom relief within days, improving IPSS by ~4-6 points.
Our position
- Reasonable as a short-term bridge
- Avoid open-ended use beyond ~1 year — favor a definitive procedure
Pitfalls
- Orthostatic hypotension — worst with doxazosin/terazosin
- Intraoperative floppy iris syndrome — tell the eye surgeon before cataract surgery
- Retrograde ejaculation is common with tamsulosin and especially silodosin
- Long-term cognitive caution: observational studies link alpha-blocker exposure — especially tamsulosin — with dementia, but results conflict and do not prove causation
- If use extends beyond ~2 years, reassess cognition, ongoing need, orthostasis/falls, and definitive BPH options
Dosing
- Finasteride 5 mg daily
- Dutasteride 0.5 mg daily
What to expect
- Best in prostates ≥ ~30-40 mL
- Shrinks the gland by ~20-25% over 6-12 months
- Slow onset — months. Set that expectation up front
- The only class shown to reduce the risk of retention and the need for surgery
PSA effect
- Lowers PSA by ~50% — double the value to interpret it
Pitfalls
- Sexual side effects (libido, ED, ejaculatory) and gynecomastia — counsel per current safety data.
- Also our drug for prostatic bleeding (Ch 2.6).
Example
- Tamsulosin + dutasteride
Evidence
Superior to either alone for larger glands and higher progression risk — the MTOPS / CombAT lesson.
Our position
Again best viewed as a bridge to definitive therapy at our practice.
Dosing
- Tadalafil 5 mg daily
Role
Improves LUTS and treats concurrent ED.
Pitfalls
- Do not combine with nitrates.
- Caution with alpha-blockers — additive hypotension.
Dosing
- Mirabegron 25-50 mg
- Vibegron 75 mg
Sequence
- Add once obstruction and retention risk are assessed — check the PVR first (Ch 5)
Our position
- our practice strongly advises against anticholinergics (oxybutynin, solifenacin, etc.) and uses them only very infrequently.
- If storage symptoms coexist, prefer a beta-3 agonist and treat the obstruction.
Why
- Dementia
- Constipation
- Dry mouth
- Retention
- Falls — see Ch 5
Alpha-blockers
- We advise against continuing beyond roughly one year.
- Observational data raise cognitive/dementia concerns, especially with tamsulosin, but studies conflict and do not prove causation.
- If use extends beyond ~2 years, reassess cognition, ongoing need, orthostasis/falls, and definitive BPH options.
- More importantly, a man kept on a daily pill for years is a man whose obstruction was never actually fixed.
- If symptoms recur off medication, that is an indication for a definitive minimally invasive procedure (UroLift or PAE), not another year of pills.
Anticholinergics for BPH-related storage symptoms
- We strongly advise against them and use them only rarely — dementia, constipation, dry mouth, retention, falls.
- Prefer a beta-3 agonist and relieve the obstruction (Ch 5).
The rule
- Expect a ~50% drop after 6-12 months
- A rising PSA on a 5-ARI is never ignored — evaluate it
Pitfalls
- Reading a 5-ARI-suppressed PSA as if it were untreated is a classic way to miss a prostate cancer. Double it.
The habit
Ask it out loud, at every follow-up. If the answer is "managing" and the patient is bothered, offer the procedure — see the Procedural approach track.
At Associated Medical Professionals of New York the choice is driven primarily by prostate size, with ejaculatory preservation a priority: UroLift for smaller glands, PAE for larger.
Select a box to open its teaching details.
Refer for a procedure when
- Symptoms are refractory to medication
- The patient wants to get off medication
- The patient prefers a durable solution
- Complications develop — retention, bladder stones, recurrent infection or bleeding, renal compromise
Why
At our practice the choice is driven primarily by prostate size, with ejaculatory preservation a priority. Use ultrasound to measure gland volume; do not estimate procedural size by DRE.
Also assess
- Whether there is a large obstructing median lobe — it affects UroLift suitability
Our two workhorse minimally invasive options — sized by the gland
Why we choose it
- Minimally invasive implants that retract the obstructing lateral lobes and hold the prostatic urethra open
- No tissue is cut, heated, or removed — which is why ejaculation is preserved
- Preserves erectile function
- Fast recovery; usually no catheter
Best suited to
- Glands under ~50 g
- Without a large obstructing median lobe
Our experience
Why we choose it
- Typically reduces prostate size by approximately 40–50% by embolizing its blood supply through a tiny catheter
- No urethral resection; typically no catheter or a short one
- Excellent preservation of sexual function
- Treats glands that are too large for many endoscopic options
Our experience
For the large gland, PAE is our gold standard and a genuine differentiator versus hospitals that still default to a TURP.
The procedure
- Under IV sedation, not general anesthesia
- A tiny catheter is introduced through an artery in the wrist or the groin and navigated to the prostatic arteries
- Microscopic beads are injected into BOTH main prostatic arteries to block the blood supply
- The devascularized adenoma involutes over the following weeks
- Takes roughly one to two hours; the patient goes home the same day
The line patients remember
- No urethral catheter afterward — provided the patient was not already in retention going in.
- This is one of the strongest selling points for the man who is terrified of a catheter, and it distinguishes PAE from a TURP. Say it explicitly; patients assume the opposite.
What you must order before scheduling
- CT angiogram — the IR team uses it to map the prostatic arterial anatomy, which is variable and occasionally prohibitive
- Pre-PAE labs
Pitfalls
- Get these moving at the visit where you decide on PAE. A missing CTA is the single most common cause of a delayed case.
How to handle it
- Coverage is inconsistent and payers can be picky
- Start the authorization early
- Set the patient's expectations honestly
- Do not promise a date until coverage is confirmed
Our position
- Associated Medical Professionals of New York does not perform Rezūm (water-vapor therapy) or GreenLight / photoselective vaporization (PVP).
- In our experience the durability and outcomes do not match UroLift and PAE, so we do not use them.
Why it matters to you
Patients arrive having read about Rezūm. Be ready to explain why we chose differently rather than deferring the question.
Other options and where they fit
- ThuLEP (thulium laser enucleation) — size-independent enucleation with excellent durability; an option for very large glands or when tissue is needed for pathology
- TURP — the historical benchmark; still appropriate for selected moderate glands
- Aquablation — heat-free waterjet resection with an expanded role in the 2026 guideline; an option across a range of gland sizes
- Single-port robotic simple prostatectomy — very large glands, often > 100-150 g, when an endoscopic approach is not ideal
The default
These remain available and are chosen case by case, but the great majority of patients are best served by UroLift or PAE.
Lead with ejaculation
- A key advantage of UroLift and PAE is preservation of ejaculation — a major reason our practice favors them over resective procedures.
- Set this expectation up front; for many men it is the deciding factor.
Normal after any prostate procedure
- Transient hematuria
- Irritative voiding — urgency, frequency, dysuria
- Both improve over weeks
Reasons to call
- Heavy bleeding
- Clot retention
- Fevers
- Inability to void
Know it exists: TURP syndrome
Dilutional hyponatremia from absorbed hypotonic irrigant — confusion, nausea, bradycardia, visual changes. A classic risk of monopolar TURP; rare now with bipolar/saline systems.